Which has stronger valuation & earnings, NERV or HELP?

Cybin is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A Cybin N/A N/A -$148M -$3.02 N/A

Is NERV or HELP more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Cybin N/A -71.78% -64.81%

Does the media refer more to NERV or HELP?

In the previous week, Cybin had 20 more articles in the media than Minerva Neurosciences. MarketBeat recorded 23 mentions for Cybin and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Cybin's score of 1.53 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cybin 11 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, GLAS or NERV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A

Is GLAS or NERV more profitable?

Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Minerva Neurosciences N/A N/A -31.72%

Does the media prefer GLAS or NERV?

In the previous week, Glass House Brands and Glass House Brands both had 3 articles in the media. Minerva Neurosciences' average media sentiment score of 1.61 beat Glass House Brands' score of 0.63 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings & valuation, NERV or ACHV?

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A

Is NERV or ACHV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Achieve Life Sciences N/A -511.12% -82.35%

Does the media favor NERV or ACHV?

In the previous week, Achieve Life Sciences had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Achieve Life Sciences and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Achieve Life Sciences' score of 1.58 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Achieve Life Sciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor COLL or NERV?

In the previous week, Collegium Pharmaceutical had 10 more articles in the media than Minerva Neurosciences. MarketBeat recorded 13 mentions for Collegium Pharmaceutical and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Collegium Pharmaceutical's score of 0.09 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Collegium Pharmaceutical 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is NERV or PHAT more profitable?

Minerva Neurosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Phathom Pharmaceuticals -41.34% N/A -20.81%

Does the media prefer NERV or PHAT?

In the previous week, Phathom Pharmaceuticals had 11 more articles in the media than Minerva Neurosciences. MarketBeat recorded 14 mentions for Phathom Pharmaceuticals and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Phathom Pharmaceuticals' score of 0.68 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Phathom Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Minerva Neurosciences (NERV) Competitors

$4.15 -0.01 (-0.24%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.16 +0.00 (+0.12%)

As of 09/11/2026 04:10 PM Eastern

Compare

NERV vs. HELP, GLAS, ACHV, COLL, and PHAT

Should you buy Minerva Neurosciences stock or one of its competitors? Minerva Neurosciences's main competitors and comparable companies include Cybin (HELP), Glass House Brands (GLAS), Achieve Life Sciences (ACHV), Collegium Pharmaceutical (COLL), and Phathom Pharmaceuticals (PHAT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Minerva Neurosciences compare to Cybin?

Minerva Neurosciences (NASDAQ:NERV) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

Minerva Neurosciences currently has a consensus price target of $10.33, indicating a potential upside of 149.00%. Cybin has a consensus price target of $48.60, indicating a potential upside of 274.71%. Given Cybin's stronger consensus rating and higher possible upside, analysts clearly believe Cybin is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cybin is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Minerva Neurosciences' return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Cybin	N/A	-71.78%	-64.81%

Minerva Neurosciences has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market. Comparatively, Cybin has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, Cybin had 20 more articles in the media than Minerva Neurosciences. MarketBeat recorded 23 mentions for Cybin and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Cybin's score of 1.53 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cybin	11 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Cybin beats Minerva Neurosciences on 8 of the 13 factors compared between the two stocks.

How does Minerva Neurosciences compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

In the previous week, Glass House Brands and Glass House Brands both had 3 articles in the media. Minerva Neurosciences' average media sentiment score of 1.61 beat Glass House Brands' score of 0.63 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Minerva Neurosciences	N/A	N/A	-31.72%

34.6% of Minerva Neurosciences shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

Glass House Brands presently has a consensus price target of $16.00, indicating a potential upside of 102.76%. Minerva Neurosciences has a consensus price target of $10.33, indicating a potential upside of 149.00%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Minerva Neurosciences beats Glass House Brands on 4 of the 6 factors compared between the two stocks.

How does Minerva Neurosciences compare to Achieve Life Sciences?

Minerva Neurosciences (NASDAQ:NERV) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

In the previous week, Achieve Life Sciences had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Achieve Life Sciences and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Achieve Life Sciences' score of 1.58 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Achieve Life Sciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Minerva Neurosciences presently has a consensus target price of $10.33, suggesting a potential upside of 149.00%. Achieve Life Sciences has a consensus target price of $15.00, suggesting a potential upside of 112.46%. Given Minerva Neurosciences' higher possible upside, equities research analysts clearly believe Minerva Neurosciences is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Minerva Neurosciences has a beta of -0.08, meaning that its stock price is 108% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.25, meaning that its stock price is 125% more volatile than the broader market.

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

Minerva Neurosciences' return on equity of 0.00% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Summary

Achieve Life Sciences beats Minerva Neurosciences on 8 of the 14 factors compared between the two stocks.

How does Minerva Neurosciences compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

Collegium Pharmaceutical has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	0.95	$62.87M	$1.24	18.35
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

In the previous week, Collegium Pharmaceutical had 10 more articles in the media than Minerva Neurosciences. MarketBeat recorded 13 mentions for Collegium Pharmaceutical and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Collegium Pharmaceutical's score of 0.09 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Collegium Pharmaceutical	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

34.6% of Minerva Neurosciences shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Collegium Pharmaceutical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market.

Collegium Pharmaceutical has a net margin of 5.93% compared to Minerva Neurosciences' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Minerva Neurosciences	N/A	N/A	-31.72%

Collegium Pharmaceutical currently has a consensus price target of $48.50, suggesting a potential upside of 113.19%. Minerva Neurosciences has a consensus price target of $10.33, suggesting a potential upside of 149.00%. Given Minerva Neurosciences' higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Collegium Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Collegium Pharmaceutical beats Minerva Neurosciences on 12 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Minerva Neurosciences (NASDAQ:NERV) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 9.3% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Minerva Neurosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%

Minerva Neurosciences has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Phathom Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Minerva Neurosciences presently has a consensus price target of $10.33, indicating a potential upside of 149.00%. Phathom Pharmaceuticals has a consensus price target of $21.25, indicating a potential upside of 154.19%. Given Phathom Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Phathom Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Phathom Pharmaceuticals	$175.11M	3.86	-$221.25M	-$1.28	N/A

In the previous week, Phathom Pharmaceuticals had 11 more articles in the media than Minerva Neurosciences. MarketBeat recorded 14 mentions for Phathom Pharmaceuticals and 3 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.61 beat Phathom Pharmaceuticals' score of 0.68 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Phathom Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Phathom Pharmaceuticals beats Minerva Neurosciences on 12 of the 15 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$198.15M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.63%	2.57%	11.72%
P/E Ratio	-0.14	799.75	274.94	25.36
Price / Sales	N/A	960.74	685.43	116.38
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	-1.28	10.39	10.33	6.20
Net Income	-$293.42M	$2.85B	$3.50B	$358.50M
7 Day Performance	-6.32%	-3.61%	-3.32%	-2.35%
1 Month Performance	5.87%	0.72%	-0.53%	-3.23%
1 Year Performance	93.47%	3.61%	23.51%	8.79%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NERV Minerva Neurosciences	2.5858 of 5 stars	$4.15 -0.2%	$10.33 +149.0%	+93.5%	$198.15M	N/A	N/A	9	Positive News
HELP Cybin	4.625 of 5 stars	$11.60 -1.4%	$48.60 +319.0%	N/A	$859.19M	N/A	N/A	50	Trending News Insider Trade
GLAS Glass House Brands	3.3248 of 5 stars	$8.47 -5.2%	$16.00 +88.9%	N/A	$837.63M	N/A	N/A	N/A	Analyst Downgrade Short Interest Decrease
ACHV Achieve Life Sciences	3.14 of 5 stars	$8.25 +3.9%	$15.00 +81.8%	+129.2%	$817.05M	N/A	N/A	20	Positive News
COLL Collegium Pharmaceutical	3.2038 of 5 stars	$24.00 -2.5%	$51.00 +112.5%	-39.0%	$801.19M	$780.57M	19.35	210	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. HELP, GLAS, ACHV, COLL, and PHAT

How does Minerva Neurosciences compare to Cybin?

Summary

How does Minerva Neurosciences compare to Glass House Brands?

Summary

How does Minerva Neurosciences compare to Achieve Life Sciences?

Summary

How does Minerva Neurosciences compare to Collegium Pharmaceutical?

Summary

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. HELP, GLAS, ACHV, COLL, and PHAT

How does Minerva Neurosciences compare to Cybin?

Do analysts rate NERV or HELP?

Which has stronger valuation & earnings, NERV or HELP?

Do insiders and institutionals believe in NERV or HELP?

Is NERV or HELP more profitable?

Which has more volatility & risk, NERV or HELP?

Does the media refer more to NERV or HELP?

Summary

How does Minerva Neurosciences compare to Glass House Brands?

Does the media prefer GLAS or NERV?

Is GLAS or NERV more profitable?

Do institutionals and insiders believe in GLAS or NERV?

Which has preferable valuation and earnings, GLAS or NERV?

Do analysts rate GLAS or NERV?

Summary

How does Minerva Neurosciences compare to Achieve Life Sciences?

Does the media favor NERV or ACHV?

Do insiders and institutionals have more ownership in NERV or ACHV?

Do analysts rate NERV or ACHV?

Which has more volatility and risk, NERV or ACHV?

Which has stronger earnings & valuation, NERV or ACHV?

Is NERV or ACHV more profitable?

Summary

How does Minerva Neurosciences compare to Collegium Pharmaceutical?

Which has preferable valuation & earnings, COLL or NERV?

Does the media favor COLL or NERV?

Do institutionals & insiders have more ownership in COLL or NERV?

Which has more risk and volatility, COLL or NERV?

Is COLL or NERV more profitable?

Do analysts recommend COLL or NERV?

Summary

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Do insiders and institutionals believe in NERV or PHAT?

Is NERV or PHAT more profitable?

Which has more risk and volatility, NERV or PHAT?

Do analysts rate NERV or PHAT?

Which has better earnings and valuation, NERV or PHAT?

Does the media prefer NERV or PHAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools